



Fate Therapeutics, Inc.
Investor Relations Department
3535 General Atomics Ct.
Suite 200
San Diego, CA 92121
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: FATE

Last Trade:	3.02
Trade Time:	4:00 PM ET Aug 17, 2017
Change:	-0.12 (-3.822%)
Day Range	3.00 - 3.16
52-Week Range	1.80 - 5.68
Volume	164,027

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

We are a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies. Our pipeline is comprised of cell-based therapies for cancer and immune disorders. Our cellular immunotherapies are based on our novel ex vivo cell programming approach, which we apply to modulate the therapeutic function and direct the fate of hematopoietic cells.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Aug 16, 2017

[Fate Therapeutics Announces Issuance of U.S. Patent Covering Use of Viral Transduction Enhancers in Gene Therapy](#)

Aug 14, 2017

[Fate Therapeutics Reports Second Quarter 2017 Financial Results](#)

Aug 9, 2017

[Fate Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference](#)

Aug 8, 2017

[Fate Therapeutics Announces Publication of Preclinical Data in Cancer Research and FDA Clearance of Third IND for FATE-NK100](#)

Aug 7, 2017

[Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2017 Financial Results](#)

Financials [\[View all \]](#)

[Second Quarter Financial Results](#)

Mar 16, 2017

[Annual Report \(10-K\)](#)

Mar 22, 2017

[Proxy Statement \(DEF 14A\)](#)

Aug 14, 2017

[Quarterly Report \(10-Q\)](#)

May 15, 2017

[Quarterly Report \(10-Q\)](#)

Nov 7, 2016

[Quarterly Report \(10-Q\)](#)